Man Group’s Cabaletta Bio CABA Stock Holding History

Man Group’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,021	Closed	-$122K	–	1955
2022 Q4	$120K	Buy	+13,021	New	+$47.4K	﹤0.01%	1881

Other funds holding CABA

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Man Group's CABA Position: Q1 2023 in Review

Man Group sold out of Cabaletta Bio (CABA) in Q1 2023, closing a stake of 13,021 shares — an estimated $122K sold.

Man Group first reported a position in CABA in Q4 2022 and held it in 1 quarter. The position peaked at $120K in Q4 2022. 71 funds tracked by Wall St. Rank hold CABA as of Q1 2023.

Man Group reported no remaining Cabaletta Bio position as of Q1 2023 after selling out during the quarter.
Man Group sold 13,021 Cabaletta Bio shares in Q1 2023, an estimated $122K.
Man Group first reported a position in Cabaletta Bio in Q4 2022 and held it in 1 quarter.
Man Group's Cabaletta Bio position peaked at $120K in Q4 2022.
71 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.